Tara Eaton - Medical Developments General Secretary
| MVP Stock | 0.42 0.01 2.44% |
Executive
Tara Eaton is General Secretary of Medical Developments International
| Address | 4 Caribbean Drive, Scoresby, VIC, Australia, 3179 |
| Phone | 61 3 9547 1888 |
| Web | https://medicaldev.com |
Medical Developments Management Efficiency
The company has return on total asset (ROA) of (0.1121) % which means that it has lost $0.1121 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6453) %, meaning that it generated substantial loss on money invested by shareholders. Medical Developments' management efficiency ratios could be used to measure how well Medical Developments manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Medical Developments' Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 2.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 5.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Isabelle Deschamps | Rio Tinto | 54 | |
| Anna Croft | Coles Group | N/A | |
| Paul Burnside | BHP Group Limited | N/A | |
| Sarah Hunter | Wesfarmers | N/A | |
| Aleksandra Spaseska | Wesfarmers | N/A | |
| Sharbel ACA | Coles Group | N/A | |
| Amanda McVay | Coles Group | N/A | |
| Kate Thomson | Ampol | N/A | |
| Bold Baatar | Rio Tinto | 50 | |
| Meaghan Davis | Ampol | N/A | |
| Brent Merrick | Ampol | N/A | |
| Karen OFlynn | Commonwealth Bank | N/A | |
| Yvonne Chong | Ampol | N/A | |
| James Martin | Rio Tinto | N/A | |
| LLB BA | Coles Group | N/A | |
| Frances Reyk | Ampol | N/A | |
| Rebecca Keenan | Wesfarmers | N/A | |
| Nigel BCom | Commonwealth Bank | 62 | |
| Monique Macleod | Commonwealth Bank | N/A | |
| Muhammad Anwar | Aneka Tambang Tbk | 50 | |
| Simon Edmonds | Wesfarmers | N/A | |
Management Performance
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.11 |
Medical Developments Leadership Team
Elected by the shareholders, the Medical Developments' board of directors comprises two types of representatives: Medical Developments inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medical. The board's role is to monitor Medical Developments' management team and ensure that shareholders' interests are well served. Medical Developments' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medical Developments' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wayne Pearce, Head Production | ||
| Brent MacGregor, Chief Officer | ||
| Wai Chi, Head Affairs | ||
| Stefaan Schatteman, Head Europe | ||
| Anita James, Chief Officer | ||
| Greer Lucas, Head Culture | ||
| Tara Eaton, General Secretary | ||
| Matthew Cramer, Chief Chain | ||
| Scott Courtney, Chief Officer |
Medical Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medical Developments a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 38.74 M | ||||
| Shares Outstanding | 112.66 M | ||||
| Shares Owned By Insiders | 16.77 % | ||||
| Shares Owned By Institutions | 25.14 % | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 1.43 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medical Stock Analysis
When running Medical Developments' price analysis, check to measure Medical Developments' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medical Developments is operating at the current time. Most of Medical Developments' value examination focuses on studying past and present price action to predict the probability of Medical Developments' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medical Developments' price. Additionally, you may evaluate how the addition of Medical Developments to your portfolios can decrease your overall portfolio volatility.